Clinical trial
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory…
NCT00004057 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004057 |
|---|---|
| Title | Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas |
| Official title | A Phase I and Pharmacokinetic Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of Combination Therapy With Paclitaxel and L-778,123 in Patients With Recurrent or Refractory Solid Malignancies |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | L-778, 123, paclitaxel |
| Enrollment | 40 |
| Start date | Dec 1, 1998 |
| Primary completion | Dec 1, 2000 |
| Completion | Dec 1, 2000 |
| First posted | Sep 13, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: